Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 2/20 | 0.33 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL890814 | 0.89 | TSHR (0.35) | SMN1; SMN2 | |
| SCHEMBL7244954 | 0.73 | NFE2L2 (0.33) | NPC1MAPTRAB9A | |
| SCHEMBL28028214 | 0.67 | ADRA2A (0.35) | MAPTSMN1; SMN2GBA1 | |
| SCHEMBL890782 | 0.64 | KDM4E (0.36) | NPC1KDM4EMAPTRAB9AGBA1 | |
| Ammonia Solution, Strong SCHEMBL5852352 | 0.64 | NPC1 (0.44) | NPC1MAPTRAB9ASMN1; SMN2SORT1 | |
| SCHEMBL23652548 | 0.63 | MAPT (0.35) | KDM4EMAPT | |
| SCHEMBL21317877 | 0.63 | KDM4E (0.42) | NPC1KDM4EMAPTCCR5 | |
| SCHEMBL3849741 | 0.62 | SORT1 (0.45) | NPC1KDM4EMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL14345287 | 0.60 | SORT1 (0.73) | NPC1KDM4EMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL3613650 | 0.60 | GBA1 (0.47) | NPC1KDM4EMAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10179124-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| US-20180036296-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | COR THERAPEUTICS, INC. | 2018-02-08 | — | — | US | disclosed |
| US-9629831-B2 | Benzamides and related inhibitors of factor XA | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-20160317511-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | COR THERAPEUTICS, INC. | 2016-11-03 | — | — | US | disclosed |
| US-9108922-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-20140377247-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-8518977-B2 | Benzamides and related inhibitors of factor XA | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20130172310-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | MILLENNIUM PHARMACEUTICALS, INC. | 2013-07-04 | — | — | US | disclosed |
| US-20120083602-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | MILLENNIUM PHARMACEUTICALS, INC. | 2012-04-05 | — | — | US | disclosed |
| US-8063036-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| EP-1259485-B1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa | MILLENNIUM PHARM INC (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20050261346-A1 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide;modified amidine elements of high potency in vitro, excellent pharmacological and pharmaceutical properties in vivo | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-24 | — | — | US | disclosed |
| US-6835739-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-12-28 | — | — | US | disclosed |
| US-20040097561-A1 | For therapy of thrombosis | MILLENNIUM PHARMACEUTICALS, INC. | 2004-05-20 | — | — | US | disclosed |
| US-20030162690-A1 | Bood anticoagulant | COR THERAPEUTICS, INC. | 2003-08-28 | — | — | US | disclosed |
| EP-1259485-A2 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa | Millennium Pharmaceuticals, Inc. (US) | 2002-11-27 | — | — | EP | disclosed |
| US-6376515-B2 | DERIVATIVES OF A 2-((4-AMIDINYLPHENYL)-CARBONYLAMINO-1,2-PHENYLENE)-CARBONYLAMINO-) PYRIDINE; POTENT AND HIGHLY SELECTIVE ANTICOAGULANTS; BIOAVAILABILITY AND/OR SOLUBILITY; PREVENTION AND TREATMENT OF THROMBOSIS AND COAGULATION | COR THERAPEUTICS, INC. | 2002-04-23 | — | — | US | disclosed |
| US-20020002183-A1 | Derivatives of a 2-((4-amidinylphenyl)-carbonylamino-1,2-phenylene)-carbonylamino-)pyridine; potent and highly selective anticoagulants; bioavailability and/or solubility; prevention and treatment of thrombosis and coagulation | MILLENNIUM PHARMACEUTICALS, INC. | 2002-01-03 | — | — | US | disclosed |
| WO-2001064642-A2 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | COR THERAPEUTICS, INC. (US) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001064643-A2 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160317511-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | TFPI, F12, TFPI2 | NPC1 2184/4885KDM4E 1933/4885MAPT 4514/4885 |
| US-20040097561-A1 | For therapy of thrombosis | F2, F12, TFPI | NPC1 2691/4885KDM4E 2943/4885MAPT 4519/4885 |
| US-20050261346-A1 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide;modified amidine elements of high potency in vitro, excellent pharmacological and pharmaceutical properties in vivo | F2, PIGS, F12 | NPC1 2415/4885KDM4E 1358/4885MAPT 4446/4885 |
| US-20180036296-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | TFPI, F12, TFPI2 | NPC1 2184/4885KDM4E 1933/4885MAPT 4514/4885 |
| US-20140377247-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | TFPI, F12, TFPI2 | NPC1 2184/4885KDM4E 1933/4885MAPT 4514/4885 |
| US-20120083602-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | TFPI, F12, TFPI2 | NPC1 2184/4885KDM4E 1933/4885MAPT 4514/4885 |
| US-20130172310-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | TFPI, F12, TFPI2 | NPC1 2184/4885KDM4E 1933/4885MAPT 4514/4885 |
| US-20020002183-A1 | Derivatives of a 2-((4-amidinylphenyl)-carbonylamino-1,2-phenylene)-carbonylamino-)pyridine; potent and highly selective anticoagulants; bioavailability and/or solubility; prevention and treatment of thrombosis and coagulation | F2, F12, PLAT | NPC1 2797/4885KDM4E 1946/4885MAPT 4613/4885 |
| US-10179124-B2 | Benzamides and related inhibitors of factor Xa | TFPI, F12, TFPI2 | NPC1 2184/4885KDM4E 1933/4885MAPT 4514/4885 |
| US-20030162690-A1 | Bood anticoagulant | F2, SERPINC1, HABP2 | NPC1 1829/4885KDM4E 2375/4885MAPT 4272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.